Baiyunshan: Revenue and Net Profit Both Increased in 2025, Annual Dividend Payout Ratio Reached 46.32%

Reprinted from China Securities Journal · China Securities Network

On the evening of March 20, Baiyunshan released its 2025 annual report. Data shows that during the reporting period, Guangzhou Pharmaceutical Baiyunshan’s operating revenue was 77.656 billion yuan, a year-on-year increase of 3.55%; total profit was 3.69 billion yuan, up 2.28% year-on-year; net profit attributable to shareholders was 2.983 billion yuan, an increase of 5.21%. The company plans to distribute a cash dividend of 4.5 yuan (tax included) for every 10 shares to all shareholders. In 2025 (including the semi-annual period), the total cash dividends distributed will amount to 1.382 billion yuan, accounting for 46.32% of the net profit attributable to shareholders in the consolidated financial statements.

During the reporting period, Guangzhou Pharmaceutical Baiyunshan further strengthened its advantageous products, tapped into dormant varieties, and cultivated new blockbuster products. Sales revenue of products such as Xiao Ke Tang, Baoji series, Amoxicillin series, Angong Niuhuang Wan, Shujin Jianyao Wan, Anti-inflammatory and Analgesic Plaster, Methyl Orange Flavonoid, Candesartan Cilexetil Tablets, and others achieved rapid year-on-year growth.

The announcement indicates that currently, Guangzhou Pharmaceutical Baiyunshan has nearly 2,000 product specifications, with 140 exclusive varieties, and nearly 90 in-production exclusive varieties. Some core products hold leading market shares in the industry. In the future, Guangzhou Pharmaceutical Baiyunshan will focus on advantageous fields, aiming for “good varieties, good quality, and good brands,” implementing the “Good Product Plan,” and continuing to strengthen core large-scale products and high-potential varieties.

By 2025, Guangzhou Pharmaceutical Baiyunshan will focus on five major advantageous areas: malignant tumors, chronic disease management, respiratory health, immune system, and andrology medications, with over 160 projects in research and development. Among them, the Class 1.1 anti-tumor new drug BYS10 tablets has entered critical registration clinical trials; the lyophilized rabies vaccine for humans (Vero cell) has been approved for market; several milestone projects such as the reformulated Kegenliyan oral solution, Zishen Yutai Wan, children’s Xiao Chai Hu granules, and Yupingfeng tea bags have achieved significant progress.

Currently, Guangzhou Pharmaceutical Baiyunshan is committed to the “Four Modernizations” transformation: modernization, technological advancement, digitalization, and internationalization. The strategic direction of transformation is clear, and the momentum for growth transformation is progressing in an orderly manner.

Thanks to the company’s continuous deepening of its internationalization strategy, the report shows that in 2025, Guangzhou Pharmaceutical Baiyunshan’s main business revenue in Hong Kong, Macau, and overseas markets will increase by 6.93% year-on-year; gross profit margin will reach 12.16%, an increase of 4.49 percentage points compared to the previous year.

In terms of product access, Xiao Chai Hu granules successfully obtained registration certificates in Macau; Angong Niuhuang Wan successfully obtained registration in Vietnam. Regarding brand globalization, the international brand logo “WALOVI” for Wanglaoji has been launched in multiple countries, and international cans are available in Germany, Australia, Singapore, Malaysia, and other regions. In pharmaceutical commerce, relying on platforms such as Guangzhou Pharmaceutical, Guangzhou Pharmaceutical (Zhuhai Hengqin) Import & Export Co., Ltd., a complete system covering drug and medical device import wholesale and import-export supply chain services has been established.

Meanwhile, Guangzhou Pharmaceutical Baiyunshan actively builds a global cooperation network, reaching strategic agreements with companies such as Saudi Edouk International Holdings, Shanghai Baosteel Packaging Co., Ltd., Pata International Trading Co., Ltd., Korea Nongshim Group, and Japan Sanyō Industry, and launching overseas localization projects.

In 2025, Guangzhou Pharmaceutical Baiyunshan established specialized investment platforms including Guangzhou Pharmaceutical Phase II Fund, Guangzhou Pharmaceutical Liwan Fund, and Guangzhou Pharmaceutical Guangkai Fund, focusing on strategic directions such as innovative drugs, modern Chinese medicine, and high-end medical devices. Notably, the Guangzhou Pharmaceutical Phase II Fund strengthened its strategic layout in East China’s pharmaceutical distribution network by acquiring 11.04% of Nanjing Pharmaceutical. The company successfully acquired Fujian Caishantang, increasing its Chinese heritage brand count to 13; additionally, it completed the mixed-ownership reform of Baiyunshan Hanfang, optimizing governance structures. (Wang Luo)